文献速递淋巴瘤造血干细胞移植与细胞治疗

brexucabtagene autoleucel治疗复发或难治性套细胞淋巴瘤的真实世界结局:CIBMTR分析

Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis.
PubMed 文献 · Blood Adv · 2025-01-01

该研究基于CIBMTR注册数据纳入2020年7月至2022年12月接受brexu-cel治疗的476例复发/难治性套细胞淋巴瘤患者,中位随访13.5个月,总缓解率91%、完全缓解率82%,1年总生存率76%、无进展生存率63%,1年非复发死亡率累积发生率8%,真实世界结局与ZUMA-2试验一致。

要点

  • 总缓解率91%,完全缓解率82%,1年总生存率76%、无进展生存率63%。
  • 既往自体造血干细胞移植与输注后6个月内更长的缓解持续时间相关(HR 0.49)。
  • 既往苯达莫司汀与 prolonged thrombocytopenia 风险增加相关(OR 1.90)。

核心结论

  • 真实世界中brexu-cel治疗复发/难治性套细胞淋巴瘤的结局与ZUMA-2试验一致,与既往治疗类型或既往治疗线数无关。

研究设计与样本

  • 前瞻性研究,基于国际血液与骨髓移植研究中心(CIBMTR)注册数据,纳入2020年7月至2022年12月接受brexu-cel治疗的476例复发/难治性套细胞淋巴瘤患者。

主要发现

  • 中位随访13.5个月,总缓解率91%,完全缓解率82%。
  • 1年总生存率76%,1年无进展生存率63%,1年非复发死亡率累积发生率8%。
  • 既往自体造血干细胞移植与输注后6个月内更好的缓解持续时间相关(HR 0.49;95%CI 0.28-0.85),但与更高的免疫效应细胞相关神经毒性综合征风险相关(OR 1.66;95%CI 1.06-2.60)。
  • 既往苯达莫司汀与 prolonged thrombocytopenia 风险增加相关(OR 1.90;95%CI 1.13-3.21)。
  • 既往治疗线数为1-2线的患者较≥3线者复发或进展更少(HR 0.64;95%CI 0.42-1.00)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Brexucabtagene autoleucel (brexu-cel) is a chimeric antigen receptor T-cell therapy approved for relapsed/refractory mantle cell lymphoma (R/R MCL). Here, we report real-world effectiveness and safety outcomes of brexu-cel in a prospective study of patients with R/R MCL, including subgroups based on prior treatment with Bruton's tyrosine kinase inhibitor, bendamustine, or autologous hematopoietic cell transplant (auto-HCT) and number of prior therapy lines, using Center for International Blood and Marrow Transplant Research registry data. A total of 476 patients with R/R MCL who received brexu-cel between July 2020 and December 2022 were included in the analysis. With a median follow-up of 13.5 months, the overall response rate was 91% and complete response rate was 82%. One-year overall survival and progression-free survival rates were 76% and 63%, respectively. One-year cumulative incidence of nonrelapse mortality was 8%. Prior auto-HCT was associated with better duration of response within 6 months after infusion (hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.28-0.85) but greater risk of immune effector cell-associated neurotoxicity syndrome (odds ratio [OR], 1.66; 95% CI, 1.06-2.60). Prior bendamustine was associated with increased risk of prolonged thrombocytopenia (OR, 1.90; 95% CI, 1.13-3.21). In patients with 1 to 2 prior therapy lines, relapse or progression was less frequent compared with those with ≥3 prior lines (HR, 0.64; 95% CI, 0.42-1.00). Collectively, our results suggest that real-world outcomes with brexu-cel were consistent with those of the ZUMA-2 trial, regardless of prior therapy type or number of prior therapy lines.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ahmed N, Thiruvengadam SK, Hamadani M, et al. Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis. Blood Adv. 2025. PMID: 40706035. doi:10.1182/bloodadvances.2024015014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。